Clinical trials: Alopecia Areata
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety…
- Trial name
- NCT07076706
- Testing
- minoxidil + finasteride
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Androgenetic Alopecia
Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant
This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of Human Platelet Lysate (HPL) in subjects with Androgenetic Alopecia undergoing hair transplantation.
- Trial name
- NCT01644422
- Testing
- Autologous Human Platelet Lysate, Standard hair follicle transplant
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Kasiak Research Pvt. Ltd.
Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
The aim of this study is to determine the bioequivalence of 5 x 0.1 milligram (mg) capsules compared to 1 x 0.5 mg capsule of dutasteride in healthy male subjects.
- Trial name
- NCT01929330
- Testing
- GI198745 0.1 mg, GI198745 0.5 mg
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia, Pattern Baldness
Evaluation of the Niostem Headset for Hair Growth and Hair Quality
This double-blind, randomized, placebo-controlled clinical trial evaluates the Niostem headset, an electronic device designed to support hair growth, reduce hair loss, and improve hair quality.
- Trial name
- NCT06994819
- Testing
- niostem headset (Active)
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Mane Biotech GmbH
Androgenetic Alopecia
Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction
Androgenetic alopecia is the most common type of alopecia in both men and women. About 80 % of Caucasian men and 40-50 % of Caucasian women are affected by androgenetic alopecia.
- Trial name
- NCT03388840
- Testing
- Adipose derived stem cells suspention, Platelet rich plasma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Androgenetic Alopecia
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp
- Trial name
- NCT06149221
- Testing
- NTAP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dr. Peter C. Friedman
Alopecia Areata
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
- Trial name
- NCT04784533
- Testing
- CTP-543
- Where
- 39 sites in United States
- Volunteers
- 317 people
- Sponsor
- Concert Pharmaceuticals
Androgenetic Alopecia
Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss
HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair growth in men with tendencies for hair loss.
- Trial name
- NCT02150187
- Testing
- HCap Formula
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Family Marketing
Breast Cancer
Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or…
- Trial name
- NCT01300871
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Alopecia Areata
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
Alopecia areata is the second most common cause of hair loss following androgenic alopecia. It is affecting 2% of global population with an increasing prevalence.
- Trial name
- NCT06088147
- Testing
- Methotrexate, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Al-Azhar University
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body.
- Trial name
- NCT05398809
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Androgenetic Alopecia
Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers
This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair…
- Trial name
- NCT06841458
- Testing
- Oral Supplement
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Hair Loss
For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers
This study is to evaluate differences in the gut and follicle/scalp microbiome signature in AGA compared to a non-AGA population.
- Trial name
- NCT07716748
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Skin Centre
Alopecia, Chemotherapy-induced Alopecia
A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads
Eligible patients will be recruited prior to initiation of chemotherapy for any stage breast or gynecologic cancer. Patients will undergo training in the use of the AMMA Portable Scalp Cooling System and will use the device…
- Conditions
- Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
- Trial name
- NCT05365243
- Testing
- AMMA Portalbe Scalp Cooling System
- Where
- United States
- Sponsor
- Cooler Heads Care Inc.
Alopecia Areata
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
- Trial name
- NCT07749716
- Testing
- Drug: VC005 tablets, VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Androgenic Alopecia
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
To investigate and compare the safety and effectiveness of the ARTAS™ System to manual hair follicle implantation method following a nine month period of post-procedure evaluation.
- Trial name
- NCT02914587
- Testing
- ARTAS System, Manual Implantation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Restoration Robotics, Inc.
Alopecia
Treatment of Androgenetic Alopecia in Men for 24 Weeks
A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment.
- Trial name
- MINOX (NCT04721548)
- Testing
- Minoxidil Topical Foam
- Where
- Brazil
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Alopecia Areata, Social Anxiety
The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata
This study investigates the impact of mindfulness based cognitive therapy (MBCT) on social anxiety in adults with alopecia areata. A single-group case-series design will be adopted.
- Trial name
- NCT03873155
- Testing
- Mindfulness Based Cognitive Therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Androgenetic Alopecia
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
This study is designed to explore the efficacy and safety of DA-4001 after topical application in male patients with androgenetic alopecia Design : Randomized, double-blind, active-controlled study Investigational Product …
- Trial name
- NCT02280603
- Testing
- DA-4001C, 5% minoxidil
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Dong-A ST Co., Ltd.